bims-rebome Biomed News
on Management of bone metastases
Issue of 2026–11–01
eight papers selected by
Alberto Selvanetti, Azienda Ospedaliera San Giovanni Addolorata



  1. World J Surg Oncol. 2026 Aug 01. pii: 408. [Epub ahead of print]24(1):
       BACKGROUND: Bone metastases a represent a challenge in the oncological management of patients as the complications can be severe, as fractures or neurological impairment in spinal metastases. Recommendations on the management of bone metastases are constantly being improved. However, there are few recent prognostic data on bone metastases in the literature to assess the impact of advances in oncological treatment on patient survival.
    HYPOTHESIS: An analysis of the activity of an MDT (Multidisciplinary Team Meeting) over 2 years could provide recent data regarding prognosis of patients presenting with bone metastasis.
    MATERIALS AND METHODS: This is a retrospective study of patients presented at an MDT from 2020 to 2021 in a university hospital. The objectives were to describe a representative cohort of patients with bone metastasis and the therapeutic decisions made (cementoplasty/radiotherapy/surgery) and patient survival according to tumor type, location of bone metastasis (spine/pelvis/other).
    RESULTS: Nine hundred ninety-two presentations of 630 patients were analyzed. The most frequent primary cancer was bronchopulmonary, followed by breast, myeloma, prostate and thyroid. 85% of patients had a spinal lesion, 51% a pelvic lesion and 52% another bone site. 49% of patients underwent radiotherapy, 39% cementoplasty and 22% surgery. Median survival was 17 months. Bronchopulmonary and prostate tumors patients had a poorer prognosis. 37% of operated patients died within 6 months of follow-up.
    CONCLUSION: This study provides a description of bone MDT meeting activity in a university hospital setting, and gives a picture of the volume of activity, prognostic factors and decisions taken with significant recourse to cementoplasty, compared with older series. The presence of bone metastases still represents a turning point in the progression of oncological diseases.
    LEVEL OF EVIDENCE: IV, retrospective study.
    Keywords:  Bone neoplasms; Cementoplasty; Follow-up study; Metastasis; Prognosis study
    DOI:  https://doi.org/10.1186/s12957-026-04531-z
  2. Crit Rev Oncol Hematol. 2026 Oct 24. pii: S1040-8428(26)00547-0. [Epub ahead of print] 105660
      Bone metastases represent a major source of morbidity in advanced solid tumors, leading to skeletal-related events (SREs), pain, and impaired quality of life. Although guidelines recommend the use of bone-modifying agents (BMAs) to prevent SREs, real-world data consistently show delayed initiation, inconsistent dosing, and poor treatment persistence for these agents. This ongoing undertreatment contributes to preventable skeletal complications, greater healthcare utilization, and diminished patient outcomes. Denosumab and bisphosphonates remain the cornerstone of bone-targeted therapy. Recent evidence indicates that sustained BMA use is strongly associated with preserved functional status, reduced bone pain, and potentially improved survival. However, access and affordability continue to limit optimal use in many settings. The introduction of denosumab biosimilars offers an important opportunity to address these barriers. Phase III trials across multiple denosumab biosimilars developed by Sandoz, Samsung Bioepis, Celltrion, and Fresenius Kabi have shown equivalent efficacy, safety, and immunogenicity to the reference denosumab, with comparable lumbar spine bone mineral density gains and low rates of adverse events. Budget-impact modeling projects substantial cost savings and expanded patient access, reinforcing their role in reducing financial toxicity and promoting more equitable bone health care. Optimal management of bone metastases requires coordinated, multidisciplinary care involving oncologists, dentists, nurses, pharmacists, radiologists, rehabilitation specialists, supportive and palliative care teams. Such collaboration ensures timely BMA initiation, preventive dental evaluation, adherence monitoring, and continuity of therapy across systemic treatment lines. Integrating biosimilars within structured, patient-centered care pathways offers a sustainable strategy to close existing treatment gaps and improve outcomes for patients with bone metastases.
    Keywords:  Biosimilar; bone metastases; cancer; denosumab; multidisciplinary
    DOI:  https://doi.org/10.1016/j.critrevonc.2026.105660
  3. J Clin Med. 2026 Oct 09. pii: 7780. [Epub ahead of print]15(20):
      Background: Prognostic models for metastatic spinal tumors have evolved from conventional point-based scores to models incorporating treatment, laboratory, and machine-learning variables. However, comparisons in contemporary Japanese surgical cohorts remain limited. Methods: This retrospective study included 171 of 208 consecutive patients who underwent surgery for metastatic spinal tumors between January 2017 and August 2024 and had ascertainable 1-year survival status. Seven prognostic systems were compared using receiver operating characteristic area under the curve (AUC) analysis for 90-day and 1-year survival. Pairwise AUC comparisons were adjusted using the Holm method. Calibration and Brier scores were also assessed for the Skeletal Oncology Research Group (SORG) machine learning algorithm (MLA). Results: For 90-day survival, AUCs were 0.77 (95% confidence interval [CI], 0.58-0.95) for the SORG MLA and 0.76 (95% CI, 0.60-0.91) for the New Katagiri score. For 1-year survival, AUCs were 0.79 (95% CI, 0.72-0.86) for the New Katagiri score, 0.76 (95% CI, 0.68-0.83) for the SORG classic scoring algorithm, and 0.74 (95% CI, 0.66-0.82) for the SORG MLA. After Holm adjustment, no significant pairwise differences were found among these three models at either prediction horizon. SORG MLA calibration deviated from perfect calibration. Conclusions: In this single-center surgical cohort, the New Katagiri score and SORG models showed higher discrimination than several conventional scoring systems. However, these findings do not establish model equivalence or the clinical benefit of model-guided decisions. Broader external validation and assessment of clinical utility are needed.
    Keywords:  New Katagiri score; SORG classic scoring algorithm; SORG machine learning algorithm; metastatic spinal tumor; prognostic scoring system
    DOI:  https://doi.org/10.3390/jcm15207780
  4. J Neuroendocrinol. 2026 Nov;pii: e70301. [Epub ahead of print]38(11):
      Tumors of neuroendocrine origin are a heterogenous group of related neoplasms which can arise from anywhere in the body. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status and grade (Ki-67 expression and/or mitotic rate), with significant prognostic variability accordingly. Historically, the prevalence of bone metastasis is reported to be 6%-12% based on "first generation" (i.e., 111Indium pentetreotide [Octreoscan®]) somatostatin receptor imaging (SSRI). We conducted a retrospective cohort study including patients with well-differentiated NENs to determine the clinical and imaging characteristics of osseous metastases when evaluated with higher-sensitivity 68Gallium-DOTATATE positron emission tomography (PET) scans, as well as determining fracture prevalence in selected sub-cohorts. We also developed a risk score analysis to assess risk of fracture in this cohort. Four hundred twenty-four patients were identified for inclusion. The median age was 61 years. Most patients were asymptomatic (64%), had sclerotic lesions (77%), Krenning 4 (71%), and had >3 sites (69%) of osseous disease. A high proportion of patients had osseous metastases at sites with high risk for fracture, including vertebra (82%), pelvis (63%), and peri-trochanteric femur (34%). Fifty-seven patients (13%) in the entire cohort suffered a fracture. Fracture prevalence was significantly lower in small bowel neuroendocrine tumors (NETs, 7%) and Grades 1 and 2 disease (8% and 9%, respectively), with higher prevalence in pancreatic NETs, paragangliomas/pheochromocytomas, lung carcinoid, and Grade 3 disease (≥20% for each; p-values <.05). Our study showed that the rate of osseous metastatic disease approximates 20% in well-differentiated NENs. Most bone metastases are asymptomatic and the risk of fracture is variable based on the primary site of disease and tumor grade. Our novel risk score analysis for fracture was designed to assist clinician decision making as to management of bone metastasis in this patient population.
    Keywords:  68Ga‐DOTATATE; PET/CT; bone metastasis; neuroendocrine neoplasm; neuroendocrine tumor
    DOI:  https://doi.org/10.1111/jne.70301
  5. J Nucl Med Technol. 2026 Oct 27. pii: jnmt.126.273620. [Epub ahead of print]
      Bone metastases are a significant source of morbidity in advanced malignancy, particularly in prostate cancer, because osteoblastic metastases can cause pain, skeletal-related events, and quality-of-life impairment. Bone-targeting radionuclide drugs are also effective in the treatment of increased bone turnover and were first developed as β-emitters for palliation but have been developed in recent years as α-emitters with proven survival benefit. This review covers the biology, history, and mechanism of action of the approved bone-targeting radiopharmaceuticals (89Sr-chloride, 153Sm-lexidronam, 223Ra-dichloride). Special focus is placed on the only bone-targeting radiopharmaceutical currently approved in the United States-223Ra-dichloride-including patient selection, administration, radiation safety, and follow-up. 223Ra, a calcium analog with a short α-particle path length, high linear energy transfer, and marrow-sparing properties, is valuable in the treatment of metastatic androgen pathway modulator-resistant prostate cancer (formerly metastatic castration-resistant prostate cancer) with bone-predominant disease and symptoms. The practical aspects of nuclear medicine are emphasized, such as imaging confirmation, laboratory value thresholds, written instructions, room preparation, contamination control, discharge instructions, and posttreatment monitoring. Bone-targeting radiopharmaceutical therapy has increasingly attractive options beyond palliation with new combination and sequencing treatment options involving prostate-specific membrane antigen-targeted therapy. The lessons learned from the shift from "β-blasts" to "α-bombs" provide a potential pathway to more effective current treatment and a new generation of targeted radiopharmaceutical therapy.
    Keywords:  223Ra-dichloride; bone-targeting radiopharmaceutical therapy; prostate cancer bone metastases
    DOI:  https://doi.org/10.2967/jnmt.126.273620
  6. Neurosurgery. 2026 Oct 30.
       BACKGROUND AND OBJECTIVES: Pathological vertebral compression fractures (VCFs) are a common and debilitating complication of metastatic cancer. Percutaneous pedicle screw fixation (PPSF) with cement augmentation is increasingly used to stabilize these fractures, but long-term construct durability and associated clinical outcomes remain incompletely defined. We sought to characterize the long-term mechanical durability of cement-augmented PPSF for oncological VCFs, evaluate outcomes, and explore factors associated with revision surgery.
    METHODS: We conducted a retrospective review of patients with cancer who underwent cement-augmented PPSF at a tertiary cancer center between 2015 and 2020. The primary outcome was implant failure requiring return to the operating room for revision stabilization. Cumulative incidence of revision was estimated. Associations between clinical and radiographic variables and revision were evaluated using univariable competing-risks regression. Secondary outcomes included pain scores, functional status, strength, and neurological measures assessed pre- and post-operatively.
    RESULTS: A total of 240 patients with 241 surgeries were included (mean age 62.8 years). Median follow-up among surviving patients was 5.0 years. Five patients (2.1%) required revision surgery. Increasing age was associated with higher risk of revision in the univariable analysis (hazard ratio 1.12, 95% CI: 1.01-1.24, P = .046), while other investigated factors were not significantly associated with failure requiring revision. Significant improvements in pain and functional status were observed.
    CONCLUSION: Cement-augmented PPSF demonstrated long-term durability for stabilization of oncological VCFs, with a low rate of revision surgery. Mechanical stability was accompanied by improvements in pain and functional status. Increasing age demonstrated an association with increased revision rates, although the low number of events limits definitive identification of predictors of failure.
    Keywords:  Cement-augmented pedicle screw; Kyphoplasty; Pathological compression fracture; Pedicle screw; Percutaneous pedicle screw; Spine metastases; Spine oncology
    DOI:  https://doi.org/10.1227/neu.0000000000004271
  7. Cancers (Basel). 2026 Oct 12. pii: 3285. [Epub ahead of print]18(20):
      Background: Pathologic fractures of the humerus due to metastatic disease cause severe pain, loss of function and reduced quality of life. Surgical treatment is predominantly palliative and aims to achieve rapid pain relief, early functional recovery and minimal treatment-related morbidity. The photodynamic bone stabilization system (IlluminOss®) is a minimally invasive, radiolucent, intramedullary device that may address these needs. Methods: This retrospective analysis of prospectively collected data from two centers included 51 patients with 52 pathologic humeral lesions (completed or impending fractures) treated with photodynamic intramedullary stabilization between 2013 and 2025. Baseline variables comprised demographics, Eastern Cooperative Oncology Group (ECOG) performance status, comorbidities, pain (numeric rating scale, NRS) and function (Musculoskeletal Tumor Society Upper Extremity Score, MSTS-UE; Toronto Extremity Salvage Score, TESS). Lesion characteristics, operative details, in-hospital course, follow-up outcomes (TESS, patient satisfaction/quality of life) and long-term endpoints (survival, complications) were recorded. Results: The study cohort (25 women, 26 men; mean age 68.5 years) represented a highly palliative population with advanced, disseminated malignant disease. Of the 52 humeral lesions, 35 (67.3%) presented as pathological fractures, whereas 17 lesions (32.7%) were classified as impending fractures due to extensive osteolysis. Among the impending fractures, Mirels scores ranged from 8 to 10, with three lesions scoring 8, eight lesions scoring 9, and six lesions scoring 10. ECOG performance status was 0-2 in 75.0% and 3-4 in 25.0% of patients. Preoperative pain was high (mean NRS 7.1) and function markedly reduced (median MSTS-UE 9.5/30; median TESS 36.5/100). Postoperatively, pain improved significantly from NRS 7.1 to 2.0 (p < 0.001). MSTS-UE increased from a median of 9.5 to 20 (p < 0.001). Follow-up showed further functional improvement with an increased TESS of 36.5 to 61 (p < 0.001), high patient satisfaction and subjective improvement in quality of life. Kaplan-Meier analysis (n = 44) demonstrated a median survival of 6 months for ECOG 0-2 and 3 months for ECOG 3-4. Implant failure (Henderson type III) occurred four times (7.7%) and was successfully revised with plate and/or screw osteosynthesis or diaphyseal replacement. Conclusions: Photodynamic intramedullary stabilization provides effective treatment for selected pathologic humeral lesions with low implant failure rate, offering rapid pain relief, functional improvement and low perioperative morbidity. Implant failure in complex fracture morphologies highlights the need for morphology-adapted indication and consideration of supplemental fixation in high-risk cases.
    Keywords:  bone metastases; multiple myeloma; palliative orthopedic oncology; pathologic humeral fracture; photodynamic intramedullary bone stabilization; skeletal-related events
    DOI:  https://doi.org/10.3390/cancers18203285
  8. Semin Nucl Med. 2026 Oct 29. pii: S0001-2998(26)00190-X. [Epub ahead of print]
      Bone metastases are a major cause of pain, skeletal complications, marrow compromise and mortality in advanced prostate cancer. The therapeutic biology of skeletal disease is heterogeneous: malignant epithelial cells expressing prostate-specific membrane antigen (PSMA) coexist with osteoblasts, osteoclasts, reactive mineralising bone and variable marrow infiltration. Radium-223 dichloride is a bone-seeking alpha emitter with randomised evidence of overall-survival benefit in selected men with metastatic castration-resistant prostate cancer (mCRPC), whereas PSMA-targeted radioligand therapy delivers radiation to PSMA-expressing tumour deposits in bone and soft tissues. Their mechanistic complementarity has motivated sequential and concurrent strategies, but complementary localisation does not itself establish clinical synergy. This review critically integrates ALSYMPCA, ERA-223, PEACE-3, VISION, TheraP, PSMAfore, RALU and AlphaBet, together with radiobiology, molecular imaging, marrow and skeletal toxicity, dosimetry and evolving therapeutic sequencing. The final 133-patient retrospective RALU report describes the safety and outcomes observed after radium-223 followed by lutetium-177-PSMA in selected heavily pretreated patients; AlphaBet reports preliminary safety and antitumour activity with concurrent lutetium-177-PSMA-I&T and radium-223 in a single-arm early-phase study. Neither provides randomised evidence of an incremental survival benefit for dual-radionuclide treatment. Conversely, PEACE-3 establishes an overall-survival benefit for radium-223 combined with enzalutamide under contemporary bone-protective practice, whereas ERA-223 underscores the fracture hazards of inappropriate combinations. Future trials must integrate lesion-level imaging, whole-body disease phenotype, marrow reserve, patient-reported outcomes, competing systemic treatments and personalised radiation exposure. The most defensible clinical strategy is evidence-weighted selection of radionuclide therapy according to disease distribution and treatment history, with concurrent dual-radionuclide approaches restricted to appropriately governed trials.
    Keywords:  Bone metastases; Dosimetry; Metastatic castration-resistant prostate cancer; PSMA-targeted radioligand therapy; Radiobiology; Radium-223
    DOI:  https://doi.org/10.1053/j.semnuclmed.2026.10.003